NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 03/02/2021 13:26
Last Report Issued 02/11/2021 08:32

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 1269SP-POS
Patient ID 1269SP-POS
Chain 21000353
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 21000353

Received 02/11/2021 08:25

Sample ID 21000353-001
Matrix Serum or Plasma
Patient Name 1269SP-POS
Patient ID 1269SP-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
1269SP Clobazam and Metabolite, Serum/Plasma				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Clobazam	50	ng/mL	20	
Synonym(s): Frisium®; Urbanyl®; Onfi®; Sympazan				
Clobazam is a benzodiazepine drug used as an anxiolytic and antiseizure medication. It is also employed as an adjunctive therapy for the treatment of seizures in patients with Lennox-Gastaut syndrome. The average (range) peak plasma concentrations reported following a single 20 mg dose was 465 (222-709) ng/mL. Reported average steady-state plasma concentrations of 1076 ng/mL and 2884 ng/mL were reported following 40 mg/day and 160 mg/day doses, respectively. The mean concentrations of clobazam did not differ between CYP2C19 extensive and poor metabolizers. The recommended therapeutic range for clobazam is 30-300 ng/mL.				
Desmethylclobazam	50	ng/mL	30	
Synonym(s): Clobazam Metabolite				

Results for sample 21000353-001 are continued on next page

NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Sample ID 21000353-001
Matrix Serum or Plasma
Patient Name 1269SP-POS
Patient ID 1269SP-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
N-desmethylclobazam is the primary pharmacologically active metabolite of Clobazam, a benzodiazepine drug used as an anxiolytic and antiseizure medication. The average (range) peak plasma concentrations reported following a single 20 mg dose was 88 (61-146) ng/mL. Reported average steady-state serum/plasma concentrations of 2783 ng/mL and 11020 ng/mL were reported following 40 mg/day and 160 mg/day doses, respectively. Excluding poor metabolizers decreased the mean N-desmethylclobazam concentration. The N-desmethylclobazam/clobazam ratio has been reported to be 5 times higher in poor metabolizers than in extensive metabolizers. The recommended therapeutic range for N-desmethylclobazam is 300-3000 ng/mL. Poor metabolizers or patients on CYP3A4 inducers and/or CYP2C19 inhibitors have been reported to have elevated concentrations of N-desmethylclobazam and increased adverse reactions.				

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.